REQUEST FOR SUPPORT

17TH EUROPEAN MEETING ON HIV & HEPATITIS

ROME, ITALY • 22 - 24 MAY 2019
INTRODUCTION

The European Meeting on HIV & Hepatitis is the premier European platform for clinicians, allied healthcare providers, researchers and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.

KEY FACTS AND FIGURES

>300 highly motivated participants from >40 countries
61% returning participants
Highly interactive, stimulating, informal scientific setting
>100 submitted abstracts

WHO ATTENDS THE MEETING

<table>
<thead>
<tr>
<th>Role</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinician</td>
<td>21%</td>
</tr>
<tr>
<td>Researcher</td>
<td>34%</td>
</tr>
<tr>
<td>Virologist</td>
<td>24%</td>
</tr>
<tr>
<td>Student</td>
<td>5%</td>
</tr>
<tr>
<td>Lab technician</td>
<td>6%</td>
</tr>
<tr>
<td>Other</td>
<td>10%</td>
</tr>
</tbody>
</table>

UNIQUE MEETING FEATURES:

The European Meeting on HIV & Hepatitis:

- Attracts a heterogeneous group of healthcare providers and scientists from different regions in Europe
- Stimulates pan-European collaborations and networks
- Is a stepping stone for early career investigators
The European Meeting on HIV & Hepatitis is the premier European platform for clinicians, allied healthcare providers, researchers and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.

Founded seventeen years ago as the European HIV resistance workshop, the meeting evolved to embrace all aspects of clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology and public health aspects of HIV, HBV and HCV infections throughout Europe.

In the last decade the meeting has been able to capture leading clinicians and researchers from the different regions of Europe. As such, this meeting is the only European platform where HIV treating physicians and clinical virologists get together on an annual basis to present and discuss latest research results and discuss their clinical implications in detail. The workshop puts a special emphasis on training young clinicians and scientists through clinical case discussions and parallel courses in collaboration with the European Society for Antiviral Research (ESAR).

**CHAIRS**

Roger Paredes  
MD, PhD  
Irsi Caixa Foundation  
Barcelona, Spain

Francesca Ceccherini – Silberstein, PhD  
University of Rome ‘Tor Vergata’,  
Rome, Italy

Roger Paredes  
MD, PhD  
Irsi Caixa Foundation  
Barcelona, Spain
COMMITTEES

WORLD’S LEADING EXPERTS

The European Meeting on HIV & Hepatitis proudly collaborates with a large number of leading European and global experts in the field of HIV and viral hepatitis. By working together with our extensive global network of experts from various backgrounds in the field we can ensure to design and deliver the most relevant and state-of-the-art program.

ORGANIZING COMMITTEE

The members of the Organizing Committee (OC) are carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to develop the scientific program tailored to the needs of Healthcare professionals in the field. Furthermore, they identify clinical cases and research projects within their organizations/ network and review and select abstracts. They actively participate as session chairs and join the Q&A sessions, discussions and debates during the meeting.

Charles Boucher  
MD, PhD  
Erasmus Medical Center Rotterdam, the Netherlands

Francesca Ceccherini-Silberstein, PhD  
University of Rome ‘Tor Vergata’, Rome, Italy

Stéphane Chevaliez, PharmD, PhD  
University of Paris-Est, Paris, France

Andrea De Luca, MD  
Siena University Hospital, Siena, Italy

Stephan Dressler, MD, PhD  
European AIDS Treatment Group, Berlin, Germany

Ravindra Gupta, MD, PhD  
University College London, United Kingdom

Anne-Geneviève Marcelin, PharmD, PhD  
Université Pierre et Marie Curie, Paris, France

Roger Paredes, MD, PhD  
Irsi Caixa Foundation, Barcelona, Spain

Carlo Federico Perno, MD, PhD  
University of Milan, Milan, Italy

Jonathan Schapiro, MD  
Sheba Medical Centre, Tel Aviv, Israel

Charles Boucher  
MD, PhD  
Erasmus Medical Center Rotterdam, the Netherlands

Francesca Ceccherini-Silberstein, PhD  
University of Rome ‘Tor Vergata’, Rome, Italy

Stéphane Chevaliez, PharmD, PhD  
University of Paris-Est, Paris, France

Andrea De Luca, MD  
Siena University Hospital, Siena, Italy

Stephan Dressler, MD, PhD  
European AIDS Treatment Group, Berlin, Germany

Ravindra Gupta, MD, PhD  
University College London, United Kingdom

Anne-Geneviève Marcelin, PharmD, PhD  
Université Pierre et Marie Curie, Paris, France

Roger Paredes, MD, PhD  
Irsi Caixa Foundation, Barcelona, Spain

Carlo Federico Perno, MD, PhD  
University of Milan, Milan, Italy

Jonathan Schapiro, MD  
Sheba Medical Centre, Tel Aviv, Israel

Jens Verheyen  
MD  
Institute for Immunology and Genetic, Kaiserslautern, Germany

Annemarie Wensing, MD, PhD  
University Medical Centre Utrecht, the Netherlands

Anne-Mieke Vandamme, PhD  
Katholieke Universiteit Leuven, Leuven, Belgium

Linos Vandekerckhove, MD, PhD  
University Hospital of Gent, Gent, Belgium
COMMITTEES

SCIENTIFIC COMMITTEE
The members of the Scientific Committee (SC) are hand-picked by the OC and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with topic and speaker suggestions. In addition, members of the SC participate in reviewing submitted abstracts, and play an active role during the workshop.

- **Jan Albert, MD, PhD**
  Karolinska Institute, Sweden

- **Claudia Balotta, MD**
  University of Milan, Italy

- **Carlos Beltran, MD**
  Chilean AIDS Group, Chile

- **Marina Bobkova, PhD**
  Ivanovsky Institute of Virology, Russia

- **Ricardo Camacho, PhD**
  Hospital Egas Moniz, Portugal

- **Bonaventura Clotet, MD, PhD**
  Hospital Universitari “Germans Trias i Pujol”, Spain

- **Slim Fourati, MD**
  Hôpital Henri Mondor, Université Paris XII, France

- **Jan Gerstoft, MD**
  Copenhagen University, Denmark

- **Rolf Kaiser, PhD**
  University of Cologne, Germany

- **Leon Kostrikis, PhD**
  University of Cyprus, Cyprus

- **Clive Loveday, PhD**
  ICVC Charitable Trust, Clinical Virology, UK

- **Jens Lundgren, MD**
  National University Hospital & University of Copenhagen, Denmark

- **Monique Nijhuis, PhD**
  University Medical Centre Utrecht, the Netherlands

- **Dimitrios Paraskevis, PhD**
  University of Athens, Medical School, Greece

- **Milosz Parczewski, MD, PhD**
  Pomeranian Medical University, Poland

- **Mario Poljak, MD, PhD**
  Institute for Microbiology and Immunology, Slovenia

- **Elisabeth Puchhammer, MD**
  University of Vienna, Austria

- **Juergen Rockstroh, MD**
  University of Bonn, Germany

- **Gary Rubin, MD**
  University of Toronto, Canada

- **Jean-Claude Schmit, PhD**
  Centre de Recherche Public de la Santé, Luxembourg

- **Rob Schuurman, PhD**
  University Medical Centre Utrecht, The Netherlands

- **Anders Sönnerborg, MD, PhD**
  Karolinska Institut, Sweden

- **Vincent Soriano, MD, PhD**
  University of Siena, Italy

- **Janusz Stanczak, PhD**
  University of Warsaw, Poland

- **Adrian Streinu - Cercel, MD, PhD**
  National Institute of Inf. Diseases "Prof.Dr. Matei Bals", Romania

- **Hauke Walter, MD**
  Medizinisches Labor Stendal, Germany

- **Maurizio Zazzi, PhD**
  University of Siena, Italy

- **Fabien Zoulim, MD, PhD**
  INSERM, France
NEEDS ASSESSMENT

Antiretroviral agents remain the cornerstone of HIV treatment and prevention.\[1\] Advances have been made in treatment of patients infected with HIV since the introduction of combination antiretroviral therapy.\[2\] In the last decade, combination therapy regimens have become more effective, better tolerated, and have been simplified in terms of dosing.\[3,4,5,6\] On the other hand, the introduction of direct-acting antivirals (DAA) has revolutionized the hepatitis C field. Most hepatitis C patients can now be cured, including those coinfected with HIV.\[7\] At the same time, there is renewed enthusiasm on HBV drug discovery such as new drugs that target distinct steps of the HBV life cycle, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription.\[8\]

Among people living with HIV there is a high prevalence and incidence of viral hepatitis compared to those living without, and re-infection rates following HCV cure are relatively high in co-infected persons.\[9\]

Notwithstanding the advances, people infected with HIV and/or HCV remain a patient population with unique characteristics that require special attention. There is a need to consider drug interactions requiring the collaborative expertise of HIV and viral hepatitis clinicians.\[10,11\] Lastly, novel drugs and treatment strategies require continued assessment since treatment outcomes cannot be assumed to be identical on the basis of prior studies.\[12\]

TARGET AUDIENCE

- Clinicians involved in the daily care of individuals infected with HIV, HCV and HBV
- Scientists involved in antiviral drug development, clinical virology and public health issues
- Post-graduate students

ESTIMATED NUMBER OF PARTICIPANTS

250 - 300

TARGET REGION

Europe

The objectives of the EUROPEAN MEETING ON HIV & HEPATITIS 2019

Meeting objectives

- Gather professionals in the fields of HIV and Hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice

Learning objectives

After attending this program, participants will be able to:

- Summarize recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals
- Recognize the future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients and develop new concepts for research and care strategies
PROGRAM DESCRIPTION

This international, scientific workshop consists of invited lectures, roundtable discussions, oral abstract and poster presentations. In order to ascertain an interactive workshop setting, much time allocated to discussion.

Program at a glance

**Wednesday, 22 May 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">COFFEE BREAK</a></td>
</tr>
<tr>
<td>11:00</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">LUNCH</a></td>
</tr>
<tr>
<td>13:30</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">COFFEE BREAK AND GUIDED POSTER TOUR</a></td>
</tr>
<tr>
<td>15:30</td>
<td>Round table discussion</td>
</tr>
<tr>
<td>17:00</td>
<td>Guided poster tour</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster viewing session and welcome drinks</td>
</tr>
</tbody>
</table>

**Thursday, 23 May 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">COFFEE BREAK</a></td>
</tr>
<tr>
<td>11:00</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">LUNCH</a></td>
</tr>
<tr>
<td>13:30</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">COFFEE BREAK AND GUIDED POSTER TOUR</a></td>
</tr>
<tr>
<td>15:30</td>
<td>Round table discussion</td>
</tr>
<tr>
<td>18:00</td>
<td>Adjournment</td>
</tr>
</tbody>
</table>

**Friday, 24 May 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td></td>
<td><a href="#">COFFEE BREAK</a></td>
</tr>
<tr>
<td>11:00</td>
<td>Invited lectures, Abstract - driven presentations</td>
</tr>
<tr>
<td>13:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

FORMAT

The meeting is abstract driven. It is known as an excellent platform for young investigators to present their research. To ensure the quality of accepted abstracts, all submitted abstracts go through a blind, peer-review process conducted by the members of the Organizing and Scientific Committees.
INFECTIONOUS DISEASES ONLINE

Enduring information presented at the conference will be freely accessible and widely disseminated to reach thousands of virtual participants beyond the walls of the conference center. Infectious Diseases Online is a premier online platform offering scientific materials in special topical areas and proceedings of conferences. All the content on Infectious Diseases Online is organized by workshop and date, making it easy to find.

Visitors of the website will have full access to:
- Abstract Books
- Meeting Reports
- Workshop Presentations
- Webcasts
LEARNING ASSESSMENT METHOD

To assess the meeting, Virology Education provides each delegate with a detailed feedback form to assess the speakers, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general logistics of the meeting, and more.

All the questions are then fully analyzed and a comprehensive report is created and shared with the committee members. These reports help us to better understand our delegates’ needs and how to improve the meeting in the future.

For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically.

Conference participation grants

The conference participation grants (CPG) provide healthcare professionals with the opportunity to attend a conference they would otherwise be unable to attend due to financial restrictions. All applications include a CV, a motivation letter, and potentially an abstract (requirements vary depending on the workshop). These are submitted via an independent CPG portal and are evaluated against the assessment criteria using a robust, impartial and independent peer review process. This process will ensure that the most qualified candidates will receive CPGs.

The grants are supported by the financial contributions allocated by the sponsor, who has no control, influence, or involvement in the selection process of the CPG candidates whatsoever. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management.

These grants help defray costs for registration, travel and accommodation for delegates and foster their ability to form valuable professional networks and develop vital collaborations. Conference participation grant applications will be solicited, selected and awarded by an expert Grant Review Committee.

Accreditation

We aim to submit an application to the EACCME® for CME accreditation of this event.
ACKNOWLEDGEMENTS

PARTNERS

ENDORSERS

THIS MEETING HAS PREVIOUSLY BEEN SPONSORED BY
SPONSORSHIP

SPONSOR BENEFITS

As a sponsor of the European Meeting on HIV & Hepatitis, you will have the unique opportunity to connect with clinicians and researchers from academia, research institutes and governments. Engage with potential collaborators and experts and discuss the latest advancements and information in the field of HIV and Hepatitis.

Sponsoring this program will give you the following benefits:

Visibility
- Prominent placement of your logo on conference materials (online and offline)
- Pre-event marketing and branding through:
  - Banners posted on the homepage of the website
  - Traffic generation to your website via the conference website
  - Your logo placed on monthly newsletters which are delivered to thousands of opt-in subscribers
  - Electronic advertising posted on several calendars linked to the event website

Contribution to the program
- A chance to organize satellite symposia
- Participate in discussions

Commercial benefits
- Exhibition opportunities [if available – add more information]
- Promotion option to display marketing materials such as pamphlets, flyers, postcards and other materials on the marketing table [subject to approval] [if available]

Privileges
Your contribution entitles you to the following privileges:
- Exhibition space [if available]
- Symposia inclusion [if available]
- Complimentary registrations to the event to increase your networking opportunities
- Other benefits described under various sponsorship levels
VIROLOGY EDUCATION

With over 20 years of experience, Virology Education is a leading provider of innovative scientific and educational programs worldwide. Our programs provide excellent platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of infectious diseases, pharmacology, liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing and education for medical professionals. We have developed long-standing collaborations with world-leading experts and work together with other important stakeholders to achieve the greatest impact for our programs and to provide top quality scientific content. Our programs range from international abstract-driven workshops to small and large scale educational series, masterclasses, advisory boards, expert rounds, satellite symposia, and more.

Biltstraat 106
3572 BJ Utrecht
The Netherlands
www.virology-education.com
info@virology-education.com
+31 30 230 7146

Goda Adomonis, MA
Project manager
goda@vironet.com

Wilco Keulen, PhD
Content manager
wilco@vironet.com

More than 50 programs are planned for 2018 in more than 30 different cities around the globe!

OUR IMPACT IN 2017

46 programs | 4,187 participants | 2,277 accepted abstracts
59% returning participants | 28,000+ opt in subscribers